Wide Ranks

IKT

Inhibikase Therapeutics, Inc.

2.73

Top Statistics
Market Cap 183 M Forward PE -10.92 Revenue Growth 0.00 %
Current Ratio 2.32 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5280 Enterprise / Revenue 126.06 Price To Sales Trailing12 Months 2305.34
Profitability
Profit Margins 0.00 % Operating Margins -23885.05 %
Balance Sheet
Total Cash 7 M Total Cash Per Share 1.06 Total Debt 355086
Total Debt To Equity 6.97 Current Ratio 2.32 Book Value Per Share 1.77
All Measures
Short Ratio 17.00 % Message Board Id finmb_113910012 Shares Short Prior Month 44110
Return On Equity -1.50 City Atlanta Uuid df2742fe-620d-3418-ba9f-016d7a873d41
Previous Close 2.36 First Trade Date Epoch Utc 1 B Book Value 1.77
Beta 1.12 Total Debt 355086 Volume 293330
Price To Book 1.54 Last Split Date 1 B Fifty Two Week Low 0.8500
Total Cash Per Share 1.06 Total Revenue 79570 Shares Short Previous Month Date 1 B
Target Median Price 8.00 Max Age 86400 Recommendation Mean 1.67
Sand P52 Week Change 0.3133 Operating Margins -23885.05 % Target Mean Price 7.00
Net Income To Common -18382382 Short Percent Of Float 0.0029 Implied Shares Outstanding 67 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 199530
Average Volume10days 199530 Total Cash 7 M Next Fiscal Year End 1 B
Revenue Per Share 0.0140 Held Percent Insiders 0.1046 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.36
Target Low Price 5.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.99
Open 2.40 Free Cashflow -10339925 State GA
Dividend Yield 0.00 % Return On Assets -0.7621 Time Zone Short Name EST
Trailing Eps -3.12 Day Low 2.39 Address1 3350 Riverwood Parkway SE
Shares Outstanding 67 M Price Hint 4 Target High Price 8.00
Website https://www.inhibikase.com 52 Week Change 1.91 Average Volume 501215
Forward Eps -0.2500 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 214.30 % Last Split Factor 1:6 Regular Market Day High 2.86
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 6.97
Fifty Two Week High 3.82 Day High 2.86 Shares Short 187953
Regular Market Open 2.40 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 126.06 Revenue Growth 0.00 % Shares Percent Shares Out 0.0029
Operating Cashflow -16468916 Currency USD Time Zone Full Name America/New_York
Market Cap 183 M Is_nasdaq_100 False Zip 30339
Quote Type EQUITY Industry Biotechnology Long Name Inhibikase Therapeutics, Inc.
Regular Market Day Low 2.39 Held Percent Institutions 0.1162 Current Price 2.73
Address2 Suite 1900 Enterprise To Ebitda -0.5280 Financial Currency USD
Current Ratio 2.32 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 1 M Two Hundred Day Average 1.77
Enterprise Value 10 M Price To Sales Trailing12 Months 2305.34 Forward PE -10.92
Regular Market Volume 293330 Ebitda -18979048 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders.

Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.

The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.

Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte.

Ltd.

The company was founded in 2008 and is headquartered in Atlanta, Georgia.